These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8122044)

  • 1. The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin.
    Osmak M; Eljuga D
    Res Exp Med (Berl); 1993; 193(6):389-96. PubMed ID: 8122044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diazenes as modificators of drug-resistance in tumor cells.
    Osmak M; Bordukalo T; Ristov AA; Jernej B; Kosmrlj J; Polanc S
    Neoplasma; 2000; 47(6):390-5. PubMed ID: 11263864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins.
    Siegsmund MJ; Marx C; Seemann O; Schummer B; Steidler A; Toktomambetova L; Köhrmann KU; Rassweiler J; Alken P
    Urol Res; 1999 Jun; 27(3):157-63. PubMed ID: 10422815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines.
    Choi CH; Kim HS; Kweon OS; Lee TB; You HJ; Rha HS; Jeong JH; Lim DY; Min YD; Kim MS; Chung MH
    Mol Cells; 2000 Feb; 10(1):38-46. PubMed ID: 10774745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
    de la Torre M; Hao XY; Larsson R; Nygren P; Tsuruo T; Mannervik B; Bergh J
    Anticancer Res; 1993; 13(5A):1425-30. PubMed ID: 7902062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collateral resistance or sensitivity of human larynx carcinoma HEp2 cells resistant to cis-dichlorodiammineplatinum (II) or vincristine sulfate.
    Osmak M
    Neoplasma; 1992; 39(3):197-202. PubMed ID: 1528326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of the glutathione/glutathione-S-transferase detoxification system in melphalan resistant human prostate cancer cells.
    Ripple M; Mulcahy RT; Wilding G
    J Urol; 1993 Jul; 150(1):209-14. PubMed ID: 8510259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
    Nomura T; Yamasaki M; Nomura Y; Mimata H
    Oncol Rep; 2005 Oct; 14(4):993-7. PubMed ID: 16142363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines.
    Lock RB; Hill BT
    Int J Cancer; 1988 Sep; 42(3):373-81. PubMed ID: 3417366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of carboplatin-resistant sublines derived from human larynx carcinoma cells.
    Osmak M; Bizjak L; Jernej B; Kapitanović S
    Mutat Res; 1995 Aug; 347(3-4):141-50. PubMed ID: 7565905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH; Lewis AD; Ehsan MN; Sikic BI
    Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifactorial molecular mechanisms are involved in resistance of preirradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine.
    Osmak M
    Neoplasma; 1993; 40(2):97-101. PubMed ID: 8102478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
    Masanek U; Stammler G; Volm M
    Anticancer Drugs; 1997 Feb; 8(2):189-98. PubMed ID: 9073315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of a cisplatin-resistant human neuroblastoma cell line.
    Yasuno T; Matsumura T; Shikata T; Inazawa J; Sakabe T; Tsuchida S; Takahata T; Miyairi S; Naganuma A; Sawada T
    Anticancer Res; 1999; 19(5B):4049-57. PubMed ID: 10628353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
    Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
    Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
    Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
    Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy.
    Dong Y; Berners-Price SJ; Thorburn DR; Antalis T; Dickinson J; Hurst T; Qiu L; Khoo SK; Parsons PG
    Biochem Pharmacol; 1997 Jun; 53(11):1673-82. PubMed ID: 9264320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined antitumor effects of bee venom and cisplatin on human cervical and laryngeal carcinoma cells and their drug resistant sublines.
    Gajski G; Čimbora-Zovko T; Rak S; Rožman M; Osmak M; Garaj-Vrhovac V
    J Appl Toxicol; 2014 Dec; 34(12):1332-41. PubMed ID: 25493319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.